RxSight, Inc. (NASDAQ:RXST – Get Free Report) Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
RxSight Stock Up 2.5 %
Shares of RXST stock opened at $25.84 on Friday. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -31.13 and a beta of 1.22. RxSight, Inc. has a 12-month low of $24.64 and a 12-month high of $66.54. The firm has a fifty day moving average of $30.56 and a 200-day moving average of $41.20.
RxSight (NASDAQ:RXST – Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The business had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Research analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current year.
Institutional Trading of RxSight
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. UBS Group began coverage on shares of RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective for the company. JPMorgan Chase & Co. cut their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their target price on shares of RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reduced their price target on RxSight from $40.00 to $35.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.
Check Out Our Latest Report on RXST
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Featured Articles
- Five stocks we like better than RxSight
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Why Invest in 5G? How to Invest in 5G Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- 3 Best Fintech Stocks for a Portfolio Boost
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.